Inside Moderna’s Biggest mRNA Test Since COVID

Moderna CEO Stéphane Bancel discusses the groundbreaking positive Phase 3 results for their individualized mRNA cancer vaccine combined with Keytruda for melanoma. He explains the personalized approach of sequencing patient tumors to teach the immune system specific cancer signatures, the engineering challenges of manufacturing a unique medicine for every patient, and Moderna's ambitious plans to expand this technology beyond melanoma to other cancers, rare genetic diseases, and autoimmune conditions.